Clinical Trial Update: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION) [Phase 3]

View source ↗

Summary

Phase III XRAY VISION trial evaluating Xevinapant with radiotherapy in resected locally advanced head and neck squamous cell carcinoma in cisplatin-ineligible p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• Xevinapant (Xevinapant)

Snippet

Sponsor: EMD Serono Research & Development Institute, Inc. | Conditions: Head and Neck Cancer | Phase 3 | Status: TERMINATED | Results posted: 2026-02-19